Cyclic Vomiting Syndrome

Back

Background

Cyclic vomiting syndrome (CVS), first described in children by Samuel Gee in 1882, is a chronic functional disorder of unknown etiology that is characterized by paroxysmal, recurrent episodes of vomiting.

The pathophysiology is unknown (see Pathophysiology and Etiology), but data suggest a strong genetic component in children with CVS, with evidence of mitochondrial heteroplasmies that predispose to CVS and other related disorders (eg, migraine and chronic fatigue syndrome). Other theories include autonomic dysfunction and, possibly, corticotropin-releasing factor (CRF) because stress is known to be a trigger for these episodes. The possible role of cannabis in causing CVS has been examined, though it remains controversial.

CVS is characterized by recurrent, discrete, stereotypical episodes of rapid-fire vomiting between varying periods of completely normal health (see Presentation). This on-and-off stereotypical pattern of vomiting is nearly pathognomonic.

Because no biochemical markers for CVS have been identified, physicians must initially look for alarming symptoms and then tailor the subsequent workup accordingly (see Workup). Depending on the presenting symptoms and signs other than vomiting, different diagnostic approaches are recommended. In the absence of known pathophysiology, treatment of CVS remains empiric (see Treatment).

For ongoing support and information, families are encouraged to contact the Cyclic Vomiting Syndrome Association, which is an international voluntary organization that serves the needs of patients in the United States and Canada.

Pathophysiology and Etiology

The etiology and pathophysiology of CVS are not known. However, studies have suggested several potential brain-gut mechanisms.

Migraine-related mechanisms have been proposed.[1, 2] In one study, patients with CVS have a significantly higher prevalence of family members with migraine headaches (82% vs 14% of control subjects with a chronic vomiting pattern). Furthermore, 28% of patients with CVS whose vomiting subsequently resolved developed migraine headaches. Approximately 80% of affected patients with family histories positive for migraine respond to antimigraine therapy.[1, 2]

Mitochondrial DNA (mtDNA) mutations may be involved in the pathogenesis of CVS. Boles et al demonstrated that 86% of children with CVS and neuromuscular disease had a history of migraines on the matrilineal side. In children with CVS, 2 mtDNA polymorphisms (16519T and 3010A) are expressed with a high degree of frequency and may serve as a surrogate marker for predisposition to the disease.[3]

The 16519T polymorphism is 6 times more common in pediatric CVS patients than in control populations.[4] The 3010A polymorphism increases the likelihood of CVS in subjects with 16519T by as much as 17 times. These mtDNA polymorphisms may account for the clustering of functional conditions and symptoms in the same individuals and families. One small (and possibly underpowered) study found that adult-onset CVS, unlike pediatric CVS, CVS is not associated with these polymorphisms, suggesting a degree of genetic distinction.[2]

Sympathetic hyperresponsiveness and autonomic dysfunction also appear to contribute to the pathogenesis of CVS.[5] Many associated symptoms, such as pallor, flushing, fever, lethargy, salivation, and diarrhea, are mediated by the autonomic nervous system.[6, 7, 8] Several studies support altered autonomic function in CVS.

Rashed et al[9] and To et al[10] demonstrated heightened sympathetic cardiovascular tone in patients with CVS. Kasawinah et al reported the successful use of dexmedetomidine, an alpha2-adrenergic agonist, to treat CVS.[11] In a small study involving 6 children with CVS, all patients had sympathetic autonomic dysfunction, affecting mainly the vasomotor and sudomotor systems. Symptoms developed during tilt testing in half of these patients, suggesting that these findings may play a role in the pathophysiology of CVS.[12]

To evaluate this association with autonomic dysfunction, a cross-sectional study was performed in which the Ohio dysautonomia (ODYSA) questionnaire was administered to 21 patients with CVS (3 children) and 46 patients with migraines.[13] The 2 patient groups had similar comorbid conditions, with fibromyalgia noted in 38% of subjects with CVS, orthostatic intolerance in 47% of subjects with CVS, functional dyspepsia in 9.5% of subjects with CVS, and complex regional pain syndrome in 24% of subjects with CVS.

The main limitation of this study was that the findings were not corroborated by means of either a physical examination or standard autonomic function testing.[13] However, the findings of orthostatic intolerance are of clinical significance because the use of pharmacologic therapy (eg, fludrocortisone and beta-blockers) may be considered in these patients.

In a prospective trial in adult CVS patients, Venkatesan et al found that most subjects with CVS (90%) had impairment of the sympathetic nervous system with postural tachycardia or sudomotor dysfunction while parasympathetic nerve function was intact.[14]

In this study, 17 (85%) of 20 adult CVS subjects and 2 (10%) of 20 control subjects had abnormalities on thermoregulatory sweat testing.[14] A total of 7 (35%) patients and 1 control subject had evidence of postural tachycardia with an increase of more than 30 beats/min in heart rate (HR) on standing. Of the subjects, 18 (90%) had abnormal sudomotor function, postural tachycardia, or both. The HR response to deep breathing was normal in 19 (95%) subjects with CVS and 18 (95%) controls.

The stress response, mediated by the hypothalamic-pituitary-adrenal (HPA) axis, can also potentially induce episodes of CVS. Infectious, psychological, and physical stressors are known triggers of episodes.[15, 16, 17, 18, 19, 68] Sato et al documented increased levels of adrenocorticotropic hormone (ACTH) and cortisol, associated with extreme lethargy and hypertension, before the onset of vomiting.[20, 21, 22, 23] Furthermore, Taché showed that central CRF induced gastric stasis, emesis, or both in animals.[24]

Therefore, CRF may be a brain-gut mediator of CVS that directly connects stress and vomiting.[25] If this theory holds true, CRF receptor antagonists currently in development could theoretically ablate vomiting by blocking the CRF receptor’s vagally mediated actions.[26]

Cannabis use in CVS has received considerable attention. Chronic marijuana use has been associated with hot showers or compulsive hot water bathing and CVS, though a cause-and-effect relation has not been confirmed. The endocannabinoid system (ECS) consists of the ligands 2-AG and anandamide and the cannabinoid receptors CB1 and CB2. This system is thought to play a role in nausea and vomiting and in coping with stress.

There is considerable evidence that activation of central and peripheral CB1 cannabinoid receptors inhibits nausea and vomiting; conversely, both nausea and vomiting are frequent adverse effects accompanying CB1 receptor antagonist use in humans. These and other data strongly suggest that that tone of the ECS regulates nausea and vomiting; further studies are needed to explore this possibility more fully.[27, 28]

That CVS has a central component has been suggested by functional magnetic resonance imaging (MRI) studies using whole-brain seed-based analysis. Patients with CVS exhibited a distinct alteration in resting state functional connectivity involving connections from the cingulate and inferior frontal gyrus (IFG), a known neural correlate of nausea.[29]

In conclusion, the pathogenesis of CVS is likely to be multifactorial, with multiple genetic, autonomic, central, and environmental factors playing a role. Further studies are needed to elucidate the exact mechanisms underlying this disorder.

Epidemiology

United States statistics

The true incidence and prevalence of CVS in the United States are unknown. In central Ohio, amid a predominantly white population, the prevalence of CVS in children (evaluated by the sole pediatric gastroenterology referral center) was 0.04%.[30]

International statistics

On the basis of limited epidemiologic data, Cullen and MacDonald estimated the prevalence of periodic vomiting in western Australia to be 2.3%.[6] Similarly, Abu-Arafeh and Russell observed a prevalence of 1.9% in school-aged children in Aberdeen, Scotland.[31] Both of these figures are derived from white populations and may not accurately reflect prevalence in all races or ethnic populations. In a study performed at KEM Hospital in Pune, India, CVS accounted for 0.5% of admissions to pediatric wards during 1998-2000.

In a population-based study from Ireland, the incidence of CVS was relatively high at 3.15 cases per 100,000 children. This incidence is comparable to those of other major GI diseases of childhood (eg, Crohn disease) in Ireland.[32]

Age-, sex-, and race-related demographics

The median age at onset is 4.8 years; however, CVS has been observed in infants as young as 6 days and in adults as old as 73 years.[1] The typical interval from onset of symptoms to diagnosis is 2.7 years.[1] In adults, the average age of onset is 21 years and the average age of evaluation for recurrent vomiting 34 years.[8] Females show a slight predominance over males (female-to-male ratio, 57:43). CVS occurs in all races but seems to affect whites disproportionately.

Prognosis

Most published series indicate that CVS lasts an average of 2.5-5.5 years, resolving in late childhood or early adolescence. A few patients continue to be symptomatic through adulthood.

As early as 1898, clinicians observed that some patients went on to develop migraine headaches. That some children with CVS progress to abdominal migraines and then to migraine headaches implies that there may be a sequential progression of age-dependent manifestations of migraine.

A survey by Abu-Arafeh et al found the mean ages of children with CVS, abdominal migraines, and migraine headaches to be 5.3 years, 10.3 years, and 11.5 years, respectively.[31] This finding supports the developmental progression from vomiting to abdominal pain to headache. In unpublished data, Li and Hayes determined that nearly one third of patients develop migraines after resolution of CVS and predicted that nearly 75% would develop migraines by age 18 years.

A study of 31 patients with CVS by Hikita et al found that the median overall duration of the disorder was 66 months and that 44% of the patients seen for follow-up (25 patients) developed migraine. The authors also found abnormally high adrenocorticotropic hormone and antidiuretic hormone levels among the 25 patients for whom follow-up data were available. Significant correlations between attack duration and adrenocorticotropic hormone levels and attack duration and antidiuretic hormone levels were noted.[33]

Although patients are well about 90% of the time, CVS can be medically and socially disabling. More than 50% of patients require intravenous (IV) fluids, compared with less than 1% of patients with rotavirus gastroenteritis. The average annual cost of testing, treatment, and absenteeism totals $17,000. Children miss an average of 24 school days per year and often need home tutoring or, occasionally, home schooling. Additionally, because of its frequency during times of excitement, CVS has ruined many birthdays, holidays, and vacations.[30]

In adults, substantial morbidity is associated with CVS, perhaps because of lack of awareness and resultant delays in diagnosis. In a study of 41 CVS patients, Fleisher found that 32% were completely disabled at the time of diagnosis.[8] A total of 293 procedures were performed in the 41 patients, and none were indicative of organic etiology. In addition, 17 surgical procedures, including 10 cholecystectomies, appendectomies, exploratory laparotomies, a pyloroplasty, and a hysterectomy, were performed without any therapeutic benefit.

Adults and children with CVS also have multiple emergency department (ED) visits (see Table 1 below), and the diagnosis is often unrecognized.[34]

Table 1. Characteristics of Emergency Department Visits in Patients With Cyclic Vomiting Syndrome



View Table

See Table

History

Cycling vomiting syndrome (CVS) is characterized by recurrent, discrete, stereotypical episodes of rapid-fire vomiting between varying periods of completely normal health (see the image below). This on-and-off stereotypical pattern of vomiting is nearly pathognomonic of CVS.



View Image

Cyclic versus chronic temporal patterns of recurrent vomiting. Number of emeses is plotted over 2-month period. Chronic pattern, represented by thin d....

Although periods of complete normality typically occur between episodes, many adult patients lose the cyclic pattern of symptoms over time, and 63% of them develop inter episodic symptoms (often nausea) between episodes; this pattern is termed coalescence.[8]

The Rome IV diagnostic criteria for CVS in children include of the following, both of which must be met[35] :

Because this 2-episode cutoff resulted in a significant number of misdiagnoses, the guidelines were modified by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) as follows (all criteria must be met)[36] :

The Rome IV criteria left the minimum number of 2 episodes to diagnose CVS unchanged to promote early diagnosis. The Rome IV criteria also removed the word “nausea” from the guideline as it was difficult to assess.[35]

The Rome III criteria for CVS in adults include the following:

Supportive criteria include a history of migraine headaches and a family history of migraine headaches.

The vomiting in CVS is typically much more severe and intermittent than that observed in gastroesophageal reflux. When children with CVS were compared with children with chronic vomiting, they had a much higher peak rate of emeses per hour (12.6 vs 1.9) but far fewer episodes per month (1.5 vs 36).[1] A cutoff criterion of at least 4 emeses per hour at peak and fewer than 2 episodes per week was 92% sensitive and 100% specific for the final diagnosis of CVS.[37]

With a larger cohort, the median peak rate of emeses was still 6 times per hour.[16] Only Bacillus cereus food poisoning matches this high intensity of emesis.[30] This singularly severe vomiting (so-called cyclic vomiting pattern) typifies patients with CVS and helps point toward a disorder that is localized outside the GI tract.

The stereotypical “on-off” pattern often begins with a prodrome of nausea and pallor. Vomiting peaks in the first hour and then begins to decline over the ensuing 4-8 hours, lasting a mean of 24 hours (median, 43 hours). Episodes commonly occur in the early morning (2:00-4:00 AM) or upon awakening (6:00-8:00 AM). The recovery period from the end of vomiting to the point of being able to eat and play lasts a mere 5 hours. Despite the implication of the term “cyclic,” only one half of patients have a stable periodicity; the rest have sporadic episodes.[30]

Besides vomiting, patients may also experience other GI symptoms. Abdominal pain is present in 80% of patients and may initially be severe enough to mimic acute abdomen and result in a laparotomy.[16] Patients may also have epigastric pain secondary to peptic injury of the esophagus.

Most patients experience retching (79%) and nausea (82%). They typically describe the nausea as the most distressing symptom[1] : It is unrelenting, is completely unrelieved by vomiting, and disappears only when the child is asleep or the episode is over. Many of the behavioral symptoms commonly observed in patients with CVS (eg, fetal positioning, social withdrawal, and turning off lights and televisions) are attempts to lessen this severe nausea.[30]

Fever, diarrhea, or both are noted in approximately one third of CVS patients, complicating the differentiation of this condition from gastroenteritis. These findings are likely due to associated autonomic symptoms, which are also common, particularly lethargy (93%) and pallor (91%).[1] Lethargy may be profound, and patients may be unable to walk or talk or may appear comatose. Excessive salivation (27%) can also be dramatic.[1]

Many patients with CVS have neurologic symptoms, which support the relation between migraines and CVS. Symptoms include headache (42%), photophobia (38%), phonophobia (30%), and vertigo (26%). Because less than half the patients with CVS have classic migraine symptoms, these symptoms cannot be used as diagnostic criteria for a migraine variant.[1]

Approximately 68% of families are able to identify events that appear to precipitate a patient’s episode.[6, 16, 19, 38] The most common precipitating event is infection (41%), particularly chronic sinusitis.[30] Psychological stresses (34%) and food products, including chocolate, cheese, and monosodium glutamate (MSG), rank close behind chronic sinusitis. Positive excitement, such as birthdays, holidays, vacations, and school outings, appear to trigger more episodes than do negative stresses.

Others recognize physical exhaustion or lack of sleep (18%), atopic events (13%), motion sickness (9%), and menses (13%) as triggers.[30] Many patients experience remission in the summer, when the number of infections and school stressors decline.[39]

The terms “cyclic vomiting syndrome” and “abdominal migraine” have often been used interchangeably because of the considerable overlap in clinical criteria. Indeed, except for vomiting, the key criteria for abdominal migraines are identical to those for CVS and include the following:

Because 80% of children with CVS have abdominal pain, and 50% of those with abdominal pain vomit, many children can be diagnosed with either CVS or abdominal migraine. When both symptoms are present, the authors use the predominant or more consistent symptom as the primary label.

The following 3 additional criteria help strengthen the diagnosis of CVS[30] :

Clinical features of CVS are summarized in Table 2 below.[40]

Table 2. Clinical Features in Adults and Children with Cyclic Vomiting Syndrome



View Table

See Table

Approach Considerations

Because no biochemical markers for cyclic vomiting syndrome (CVS) have been identified, the guidelines formulated by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) suggest that physicians must initially look for alarming symptoms and then tailor the workup accordingly. Suspicious symptoms include the following:

Depending on the presenting symptoms and signs other than vomiting, different diagnostic approaches are recommended. In addition, certain subgroups of patients are thought to be at high risk for metabolic disorders. If the following conditions are met, early referral to a metabolic specialist or neurologist should be considered:

A heterogeneous group of disorders can mimic CVS, and these disorders must be excluded with systematic laboratory and radiographic testing. An analysis by Li et al identified 3 main categories to be considered in the differential diagnosis[47] :

A psychological evaluation may reveal ongoing panic, anxiety, and eating disorders, and stress management may attenuate the stress triggers.[48]

Laboratory Studies

In the evaluation of the patient for possible GI disease, screening blood work should include a complete blood count (CBC) with differential, assessment of the erythrocyte sedimentation rate (ESR), and measurement of levels of hepatic transaminases, pancreatic amylase, and lipase. Nonanatomic renal disease can be detected by means of serum blood urea nitrogen (BUN) and creatinine tests, urinalysis, and urine calcium-to-creatinine ratio.[48]

Screening for multiple metabolic and endocrine disorders can be accomplished by assessing pH and measuring levels of electrolytes, glucose, lactic acid, ammonia, amino acids, adrenocorticotropic hormone (ACTH), and antidiuretic hormone (ADH).

Urinary ketones, organic acids, ester-to-free carnitine ratio, porphobilinogen, and aminolevulinic acid may also guide diagnosis in the correct direction.[48] These metabolic and endocrine tests must be obtained during the vomiting episode to detect intermittent disorders (eg, disorder of fatty acid oxidation) or heterozygote disorders (eg, partial ornithine transcarbamylase deficiency).

All blood and urine tests must be performed before the administration of intravenous (IV) fluids containing glucose or other medical treatments.

In a postmenarchal girl, the physician must consider a beta human chorionic gonadotropin (beta-hCG) test for pregnancy.[48]

Radiography, Endoscopy, US, CT, and MRI

Imaging studies may be indicated as follows.

In evaluation for GI diseases, upper GI (UGI) radiography with small-bowel follow-through (SBFT), esophagogastroduodenoscopy (EGD), abdominal ultrasonography (US), or computed tomography (CT) and gastric-emptying scanning may provide definitive information.[48] In evaluation for neurologic or otolaryngologic diseases, sinus CT or brain MRI should be considered. CT scans may not adequately visualize the subtentorial region. Obstructive renal disease can be revealed with renal ultrasonography or CT imaging.

With a broad array of possible diagnoses and possible diagnostic approaches, an extensive evaluation may appear cumbersome. Olson and Li reported that UGI radiography followed by empiric antimigraine therapy for 2 months is the most cost-effective approach ($1600) for the initial treatment of recurrent episodic vomiting in children ($3020 for extensive diagnostic evaluation, and $1830 for empiric treatment alone).[49]

Until prospective trials are conducted, the authors’ current approach generally includes initial blood and urine screens, including metabolic screening and UGI radiography at initial presentation.

The presence of specific symptoms such as hematemesis, bilious vomiting, persistent headache, flank pain, acidosis, or uncharacteristically severe or atypical vomiting episodes should raise the clinician’s index of suspicion of an underlying disorder and should warrant a prompt and more extensive or repeat evaluation.[49] The 4 tests with the highest yield are endoscopy, sinus radiography or CT imaging, small-bowel radiography, and head CT or MRI.[48]

Approach Considerations

In the absence of known pathophysiology, treatment of cyclic vomiting syndrome (CVS) remains empiric.[16, 50] The following management strategies are used for CVS[30, 51] :

Consultation with a sympathetic gastroenterologist without drug therapy may decrease the frequency of vomiting episodes by as much as 70%.[48]

Avoidance of Triggers

In some cases of CVS, avoiding identified dietary triggers such as chocolate, cheese, and monosodium glutamate (MSG) can prevent episodes without the use of medication.[30] If psychological stressors trigger episodes, stress management techniques or benzodiazepine anxiolytics (eg, lorazepam or diazepam) may help to abort attacks in the early stages. However, avoiding common triggers such as car rides and infection may be impractical or impossible.

Sleep deprivation is also cited as a common trigger for patients with CVS and proper sleep hygiene should also be emphasized. Interestingly, a 70% decrease in frequency of episodes (placebo effect) on consultation and lifestyle changes without drug therapy has been noted.[7]

Prophylactic and Abortive Pharmacologic Therapy

Pharmacologic therapy is used to prevent episodes of vomiting or to decrease their frequency and also to abort or attenuate episodes once they begin.[52, 53, 67] Preventive medications are normally used in patients with more than a single episode of CVS per month. The mainstays of prophylactic therapy include the following:

Medications used for aborting episodes include the following:

Agents used in migraines, such as triptans, have also been effective in aborting attacks. If abortive therapy fails, supportive combinations such as ondansetron plus lorazepam or chlorpromazine plus diphenhydramine may attenuate an attack of cyclic vomiting in progress.[54] In September 2011, the US Food and Drug Administration (FDA) released an alert about the possibility of an increase in cardiac arrhythmias with the use of ondansetron, and monitoring the QT interval is recommended.

Daily prophylactic pharmacotherapy may be used to prevent episodes that occur more than once a month or if they are extremely severe and disabling (eg, lasting 3 days or longer).[55, 56] Most of these drugs are non-GI medications, such as antimigraine agents, anticonvulsants, neuroleptics, and prokinetic drugs. A family history positive for migraines predicts a high response rate (80%) to antimigraine medications; therefore, these agents are a logical first choice.[30]

The guidelines formulated by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) recommend cyproheptadine as first-line therapy in children younger than 5 years. However, cyproheptadine can cause substantial weight gain because of an increase in appetite. Amitriptyline is the first-line choice in children older than 5 years and adolescents.[30]

Although no randomized control trials have examined medications used in CVS, several open-label trials and retrospective studies support the use of amitriptyline as first-line therapy in patients with CVS who are older than 5 years. In an open-label study of 41 patients with CVS who were followed up for 1-2 years, long-term therapy with tricyclic antidepressants (TCAs) significantly reduced the frequency and duration of episodes and the number of emergency department (ED) visits and hospitalizations.[57]

In this study, 80% of patients reported overall improvement of symptoms; however, one third of the patients reported mild adverse effects that did not lead to discontinuance of the medication.[57] After 2 years of treatment, the frequency of episodes was reduced from 17.8 episodes per year to 3.3 episodes, and the duration of an episode decreased from 6.7 days to 2.2 days. The mean number of ED visits and hospitalizations decreased from 15 to 3.3 over 2 years.

In a study of 132 patients with CVS who had been monitored for 4 years, 17 subjects were identified as nonresponders to TCA therapy.[43] When compared with responders, nonresponders were significantly more likely to have a history of migraine, coexisting psychological disorders, chronic marijuana use, and reliance on narcotics for pain control between CVS episodes. These findings favor a multidisciplinary approach to these patients, with aggressive treatment of other comorbid illnesses.

One study used an Internet-based survey completed by subjects with CVS or their parents to assess the efficacy of coenzyme Q10 and amitriptyline.[58] In all, 72% of the 162 patients receiving amitriptyline and 68% of the 22 patients receiving coenzyme Q10 reported at least a 50% reduction in the frequency, duration, or severity of episodes. Patients receiving coenzyme Q10 did not have any side effects, whereas one half of the patients receiving amitriptyline reported side effects.

In this study, 21% of patients on amitriptyline discontinued treatment because of side effects.[58] The same author reported a high degree of efficacy with monitoring drug levels and titrating medications to achieve therapeutic levels in a small series of patients.[59] Combination therapy with amitriptyline and mitochondrial supplements such as coenzyme Q10 and L-carnitine were used in most of these patients.

In another study, 20 adult patients with CVS received zonisamide (median dosage, 400 mg/day) or levetiracetam (median dosage, 1000 mg/day) because TCAs alone were unsatisfactory as maintenance medications; at least moderate clinical response was reported in 15 subjects (75%), and 4 of these (20%) reported symptomatic remission during 9.5 ± 1.8 months of follow-up.[60] Newer antiepileptic agents appeared beneficial as maintenance medications for nearly three fourths of adults with CVS.

In a retrospective study of 101 adults with CVS, most patients (86%) responded to treatment with TCAs, anticonvulsants (topiramate), coenzyme Q10, and L-carnitine.[61] Nonresponse to therapy was associated with coalescence of symptoms, chronic opiate use, and more severe disease as characterized by longer episodes, a greater number of ED visits in the year before presentation, the presence of disability, and noncompliance on univariate analysis. On multivariate analysis, only compliance to therapy was associated with a response.

When prophylactic medication fails or is not taken because of the sporadic and infrequent occurrence of cyclic vomiting episodes (< 1/month), abortive agents may be taken at the onset of an attack to stop progression. These antinausea and antimigraine agents are best administered nasally, rectally, or parenterally because they are not usually tolerated by mouth during intractable emesis.[48]

Sumatriptan, a 5-hydroxytryptamine receptor 1B/1D (5-HT1B/1D) agonist used off label, has a 46% efficacy rate when administered either intranasally or subcutaneously. The subcutaneous route has fallen out of favor because of a severe associated burning sensation in the chest and neck.[62, 63]

Ondansetron, a 5-HT3 antagonist, is a potent and effective antiemetic that acts on the chemoreceptor zone in the brainstem. In CVS, it is more effective at a higher dose of 0.3-0.4 mg/kg every 6 hours and is rendered more effective in severe episodes with the use of a benzodiazepine or diphenhydramine as an adjunctive antinausea agent.[1] High-dose intravenous (IV) ondansetron has a 59% efficacy rate and ameliorates episodes more often than it aborts them.

Aprepitant, a promising tachykinin (NK-1)–receptor antagonist, is used for chemotherapy-induced emesis and could be of benefit for patients with CVS.[48]

Supportive Pharmacologic Therapy

When both prophylactic and abortive therapy fails, supportive care becomes an essential aspect of treatment during acute episodes.

IV glucose-containing fluids may diminish the severity of episodes by as much as 42%.[48] Glucose may serve as the active ingredient by truncating the ketosis. However, the abdominal pain may be severe enough to necessitate the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or narcotics once a surgical abdomen has been excluded. Caution must be exercised when narcotics are administered for moderate to severe pain and patients must be monitored to ensure that they do not become dependent on or addicted to these agents.

Chronic opiate use can result in hyperalgesia, for which various mechanisms have been proposed. Sustained morphine administration increased substance P (SP) and NK-1 receptor expression in the spinal dorsal. Morphine-induced hyperalgesia was reversed by spinal administration of NK-1 receptor antagonists in rats and mice and was observed in wild-type NK-1 receptor positive mice but not in NK-1 receptor knockout (KO) mice.[64]

The transient receptor potential vanilloid 1 (TRPV1) receptor, a molecular sensor of noxious heat, also plays an important role in the development of hyperalgesia. Administration of morphine via subcutaneously implanted morphine pellets elicited both thermal and tactile hypersensitivity in TRPV1 wild-type mice but not in TRPV1 KO mice.[65] Moreover, oral administration of a TRPV1 antagonist reversed both thermal and tactile hypersensitivity induced by sustained morphine administration in mice and rats.

Sedatives such as diphenhydramine, lorazepam, and chlorpromazine have been administered to permit sleep and to provide temporary respite from unrelenting nausea.[48] The combination of lorazepam and ondansetron appears to be more effective than ondansetron alone.

Family Support

Families are encouraged to contact the Cyclic Vomiting Syndrome Association, which is an international voluntary organization that serves the needs of CVS patients in the United States and Canada, for ongoing support and information. Various resources, including local support groups and scientific and family conferences, are available to help families understand this disorder and to provide them with coping mechanisms for battling this often disabling illness.

Complications

A study that evaluated the relationship between anxiety and health-related quality of life in children and adolescents with cyclic vomiting syndrome (CVS) reported that children and adolescents with CVS appear to be at increased risk for anxiety. Anxiety symptoms are a stronger predictor of health-related quality of life than disease characteristics in children and adolescents with CVS. Assessment and treatment of anxiety in children and adolescents with CVS may have a positive impact on health-related quality of life.[66]

Medication Summary

Medications used to prevent, ameliorate, or abort vomiting episodes include cyproheptadine, amitriptyline, topiramate, zonisamide, levetiracetam, propranolol, phenobarbital, erythromycin, ondansetron, promethazine, and prochlorperazine.

Ondansetron (Zofran)

Clinical Context:  The 5-HT3 antagonist ondansetron directly acts at the CTZ and vagal afferents from the GI tract. It attenuates or, occasionally, aborts an active episode of CVS. High doses are more effective in patients with CVS.

Promethazine (Phenergan, Phenadoz)

Clinical Context:  Promethazine is a phenothiazine derivative that possesses antihistaminic, sedative, antimotion sickness, antiemetic, and anticholinergic effects.

Prochlorperazine (Compro)

Clinical Context:  Prochlorperazine may relieve nausea and vomiting by blocking postsynaptic mesolimbic dopamine receptors through its anticholinergic effects and depressing the reticular activating system.

Class Summary

The vomiting center (VC) of the central nervous system (CNS) may be stimulated directly by gastrointestinal (GI) irritation, motion sickness, or vestibular neuritis. Increased activity of central neurotransmitters, such as dopamine in the chemoreceptor trigger zone (CTZ) or acetylcholine in the VC, appear to be major mediators of vomiting.

An emetogenic episode may initiate the release of serotonin (5-HT) from enterochromaffin cells in the GI tract. 5-HT then binds to 5-HT3 receptors, which stimulate vagal neurons that transmit signals to the VC, resulting in nausea and vomiting. Pharmacologic agents are directed to the particular etiology or mechanism that stimulates the vomiting response.

Cyproheptadine

Clinical Context:  Cyproheptadine is a nonselective antihistamine effective against CVS and migraines. It is also an appetite stimulant. Therapeutic effects are observed within 1-2 weeks. This agent is an excellent choice for children younger than 5 years.

Diphenhydramine (Benadryl)

Clinical Context:  Diphenhydramine is used for treatment and prophylaxis of vestibular disorders that may cause nausea and vomiting. It provides mild sedation, as well as antinausea and antiemetic actions synergistic with those of 5-HT3 antagonists.

Class Summary

Antihistamines may be used to prevent nausea rather than treating vomiting, though antihistamines appear to be the best of all classes in treating it once it has begun. Their effectiveness is likely due to their central anticholinergic properties that reduce activity in the vestibular nuclei. The nonsedating antihistamines (ie, those that do not cross the blood-brain barrier) do not appear to be effective in either preventing or treating nausea and vomiting. Common adverse effects can include dry mouth/nose/throat, drowsiness, and sensitivity to bright light (secondary to mydriasis). Less common adverse effects include palpitations, urinary retention, bloating, constipation, headache, and confusion. They should be taken 1 hour prior to departure.

Amitriptyline

Clinical Context:  Tricyclic antidepressants (TCAs) such as amitriptyline are excellent first-line choices in children older than 5 years. Amitriptyline has anticholinergic and sedating side effects and thus is best administered at bedtime. Cardiac arrhythmia, especially in overdose, has been described; monitoring the QTc interval both before therapy is initiated and after the target level has been reached is advised. Up to 1 month may be needed for clinical effects to become evident.

Class Summary

Tricyclic antidepressants are a complex group of drugs that have central and peripheral anticholinergic effects, as well as sedative effects. They may block the active reuptake of norepinephrine and serotonin.

Propranolol (Inderal LA, InnoPran XL)

Clinical Context:  Propranolol is a beta-adrenergic blocker and an excellent first-line agent for prophylaxis when used at low doses. It has a 57% efficacy rate, with efficacy defined as a 50% reduction in the frequency and severity of episodes. It requires 1 week for efficacy and requires gradual withdrawal over 1 week. Dosing may be monitored on the basis of a fall in presleep resting pulse from baseline; a decline of less than 15-20 beats/min indicates that the dose may be further increased.

Class Summary

Beta-blockers may reduce the frequency and severity of episodes. Propranolol is usually recommended because of its CNS penetration.

Phenobarbital

Clinical Context:  Phenobarbital may be used in patients with or without electroencephalographic (EEG) changes. A 79% response rate has been observed in patients with CVS.

Topiramate (Topamax)

Clinical Context:  Topiramate is a sulfamate-substituted monosaccharide with a broad spectrum of antiepileptic activity; it may have state-dependent sodium channel blocking action. It potentiates the inhibitory activity of the neurotransmitter GABA. In addition, topiramate may block glutamate activity and, in turn, help reduce the frequency and severity of episodes.

Zonisamide (Zonegran)

Clinical Context:  Zonegran blocks T-type calcium channels, prolongs sodium channel inactivation, and is a carbonic anhydrase inhibitor.

Levetiracetam (Keppra, Keppra XR)

Clinical Context:  Levetiracetam may facilitate GABAergic inhibitory transmission through displacement of negative modulators.

Class Summary

Agents that inhibit brain glutamate decarboxylase, which causes a decrease in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), may help reduce the frequency and severity of episodes.

Erythromycin (E.E.S., Ery-Tab, Erythrocin)

Clinical Context:  Erythromycin is a gastric prokinetic that stimulates coordinated gastric emptying. A 75% response rate has been demonstrated in patients with CVS.

Sumatriptan (Imitrex, Sumavel DosePro)

Clinical Context:  The 5-HT1B/1D agonist sumatriptan may effectively terminate an episode of CVS by constricting the cerebral vasculature. High doses are more effective in patients with CVS.

Class Summary

Antibiotics with prokinetic activity in the stomach may be used.

Lorazepam (Ativan)

Clinical Context:  Because of both their sedative properties and their antinausea effects, sedatives may be helpful. Lorazepam induces sedation and anxiolysis through central inhibition of gamma-aminobutyric acid (GABA). Its effects appear to be synergistic with the antinausea and antiemetic effects of 5-HT3 antagonists. Concomitant sedation and induction of sleep provide sustained relief from intractable nausea.

Class Summary

Some agents in this class may be used for the treatment of nausea.

What is cyclic vomiting syndrome (CVS)?What is the pathogenesis of cyclic vomiting syndrome (CVS)?What is the US prevalence of cyclic vomiting syndrome (CVS)?What is the global prevalence of cyclic vomiting syndrome (CVS)?Which patient groups have the highest prevalence of cyclic vomiting syndrome (CVS)?What is the prognosis of cyclic vomiting syndrome (CVS)?Which clinical history findings are characteristic of cyclic vomiting syndrome (CVS)?Which conditions are included in the differential diagnoses of cyclic vomiting syndrome?What are the differential diagnoses for Cyclic Vomiting Syndrome?How is cyclic vomiting syndrome diagnosed?What is the role of lab tests in the workup of cyclic vomiting syndrome?What is the role of imaging studies in the workup of cyclic vomiting syndrome?How is cyclic vomiting syndrome treated?Which factors may trigger cyclic vomiting syndrome?What is the role of medications in the treatment of cyclic vomiting syndrome?What is supportive care for cyclic vomiting syndromeWhat support and patient education resources are available for families and patients with cyclic vomiting syndrome?What are the possible complications of cyclic vomiting syndrome?Which medications are used in the treatment of cyclic vomiting syndrome?Which medications in the drug class Anxiolytics, Benzodiazepines are used in the treatment of Cyclic Vomiting Syndrome?Which medications in the drug class Antibiotics are used in the treatment of Cyclic Vomiting Syndrome?Which medications in the drug class Anticonvulsants are used in the treatment of Cyclic Vomiting Syndrome?Which medications in the drug class Beta-Adrenergic Blocking Agents are used in the treatment of Cyclic Vomiting Syndrome?Which medications in the drug class Antidepressants, TCAs are used in the treatment of Cyclic Vomiting Syndrome?Which medications in the drug class Antihistamines, 1st Generation are used in the treatment of Cyclic Vomiting Syndrome?Which medications in the drug class Antiemetic Agents are used in the treatment of Cyclic Vomiting Syndrome?

Author

Thangam Venkatesan, MD, Associate Professor of Medicine, Fellowship Director, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical College of Wisconsin

Disclosure: Nothing to disclose.

Coauthor(s)

B UK Li, MD, Professor of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Medical College of Wisconsin; Attending Gastroenterologist, Director, Cyclic Vomiting Program, Children’s Hospital of Wisconsin

Disclosure: Nothing to disclose.

Chief Editor

Carmen Cuffari, MD, Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Disclosure: Received honoraria from Prometheus Laboratories for speaking and teaching; Received honoraria from Abbott Nutritionals for speaking and teaching. for: Abbott Nutritional, Abbvie, speakers' bureau.

Acknowledgements

Jayant Deodhar, MD Associate Professor in Pediatrics, BJ Medical College, India; Honorary Consultant, Departments of Pediatrics and Neonatology, King Edward Memorial Hospital, India

Disclosure: Nothing to disclose.

Seth Marcus, MD Fellow, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Memorial Hospital, Northwestern University

Seth Marcus, MD is a member of the following medical societies: American Academy of Pediatrics and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Abhilasha Pandey, MBBS Froedtert Hospital, Medical College of Wisconsin

Disclosure: Nothing to disclose.

David A Piccoli, MD Chief of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia; Professor, University of Pennsylvania School of Medicine

David A Piccoli, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Shikha Sundaram, MD Fellow, Department of Gastroenterology, Hepatology and Nutrition, Children's Memorial Hospital of Chicago and Northwestern University

Shikha Sundaram, MD is a member of the following medical societies: American Academy of Pediatrics and American Medical Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References

  1. Li BU, Misiewicz L. Cyclic Vomiting Syndrome: a brain-gut disorder. Gastroenterol Clin N Am. 2003. 32:997-1019. [View Abstract]
  2. Boles RG, Zaki EA, Lavenbarg T, et al. Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil. 2009 Sep. 21(9):936-e72. [View Abstract]
  3. Venkatesan T, Zaki EA, Kumar N, Sengupta J, Ali M, Malik B, et al. Quantitative pedigree analysis and mitochondrial DNA sequence variants in adults with cyclic vomiting syndrome. BMC Gastroenterol. 2014 Oct 21. 14:181. [View Abstract]
  4. Zaki EA, Freilinger T, Klopstock T, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia. 2009 Jul. 29(7):719-28. [View Abstract]
  5. Gordan N. Recurrent vomiting in childhood, especially of neurological origin. Dev Med Child Neurol. 1994 May. 36(5):463-7. [View Abstract]
  6. Cullen KJ, MacDonald WB. The periodic syndrome: its nature and prevalence. Med J Aust. 1963 Aug 3. 50(2):167-73. [View Abstract]
  7. Fleisher DR. The cyclic vomiting syndrome described. J Pediatr Gastroenterol Nutr. 1995. 21 Suppl 1:S1-5. [View Abstract]
  8. Fleisher DR, Gornowicz B, Adams K, Burch R, Feldman EJ. Cyclic Vomiting Syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med. 2005 Dec 21. 3:20. [View Abstract]
  9. Rashed H, Abell TL, Familoni BO, Cardoso S. Autonomic function in cyclic vomiting syndrome and classic migraine. Dig Dis Sci. 1999 Aug. 44(8 Suppl):74S-78S. [View Abstract]
  10. To J, Issenman RM, Kamath MV. Evaluation of neurocardiac signals in pediatric patients with cyclic vomiting syndrome through power spectral analysis of heart rate variability. J Pediatr. 1999 Sep. 135(3):363-6. [View Abstract]
  11. Khasawinah TA, Ramirez A, Berkenbosch JW, Tobias JD. Preliminary experience with dexmedetomidine in the treatment of cyclic vomiting syndrome. Am J Ther. 2003 Jul-Aug. 10(4):303-7. [View Abstract]
  12. Chelimsky TC, Chelimsky GG. Autonomic abnormalities in cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr. 2007 Mar. 44(3):326-30. [View Abstract]
  13. Chelimsky G, Madan S, Alshekhlee A, Heller E, McNeeley K, Chelimsky T. A comparison of dysautonomias comorbid with cyclic vomiting syndrome and with migraine. Gastroenterol Res Pract. 2009. 2009:701019. [View Abstract]
  14. Venkatesan T, Prieto T, Barboi A, Li B, Schroeder A, Hogan W. Autonomic nerve function in adults with cyclic vomiting syndrome: a prospective study. Neurogastroenterol Motil. 2010 Dec. 22(12):1303-7, e339. [View Abstract]
  15. Fleisher DR, Matar M. The cyclic vomiting syndrome: a report of 71 cases and literature review. J Pediatr Gastroenterol Nutr. 1993 Nov. 17(4):361-9. [View Abstract]
  16. Li BU, Fleisher DR. Cyclic vomiting syndrome: features to be explained by a pathophysiologic model. Dig Dis Sci. 1999 Aug. 44(8 Suppl):13S-18S. [View Abstract]
  17. Li BU, Murray RD, Heitlinger LA, et al. Is cyclic vomiting syndrome related to migraine?. J Pediatr. 1999 May. 134(5):567-72. [View Abstract]
  18. Smith CH. Recurrent vomiting in children: Its etiology and treatment. J Pediatr. 1937. 10:719-42.
  19. Withers GD, Silburn SR, Forbes DA. Precipitants and aetiology of cyclic vomiting syndrome. Acta Paediatr. 1998 Mar. 87(3):272-7. [View Abstract]
  20. Sato T. Prevalence of Syndrome of ACTH-ADH discharge in Japan. Clin Pediatr Endocrinol. 1993. 2:7-12.
  21. Sato T, Funahashi T, Mukai M, et al. Periodic ACTH discharge. J Pediatr. 1980 Aug. 97(2):221-5. [View Abstract]
  22. Sato T, Igarashi N, Minami S, et al. Recurrent attacks of vomiting, hypertension and psychotic depression: a syndrome of periodic catecholamine and prostaglandin discharge. Acta Endocrinol (Copenh). 1988 Feb. 117(2):189-97. [View Abstract]
  23. Sato T, Uchigata Y, Uwadana N, et al. A syndrome of periodic adrenocorticotropin and vasopressin discharge. J Clin Endocrinol Metab. 1982 Mar. 54(3):517-22. [View Abstract]
  24. Tache Y. Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Dig Dis Sci. 1999 Aug. 44(8 Suppl):79S-86S. [View Abstract]
  25. Lee C, Sarna SK. Central regulation of gastric emptying of solid nutrient meals by corticotropin releasing factor. Neurogastroenterol Motil. 1997 Dec. 9(4):221-9. [View Abstract]
  26. Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high affinity corticotrophin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000. 34:171-81. [View Abstract]
  27. Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 2011 Aug. 163(7):1411-22. [View Abstract]
  28. Choukèr A, Kaufmann I, Kreth S, Hauer D, Feuerecker M, Thieme D. Motion sickness, stress and the endocannabinoid system. PLoS One. 2010. 5(5):e10752. [View Abstract]
  29. Erica A. Samuel, Arash Babaei, Anna Patel, Robert M. Siwiec, Mark Kern, Thangam Venkatesan, et al. Cyclic Vomiting Syndrome is Associated With Alterations of Brain Connectivity. Gastroenterology. May/2012. 142:S-552-S-553.
  30. Li BU, Balint JP. Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder. Adv Pediatr. 2000. 47:117-60. [View Abstract]
  31. Abu-Arafeh I, Russell G. Prevalence and clinical features of abdominal migraine compared with those of migraine headache. Arch Dis Child. 1995 May. 72(5):413-7. [View Abstract]
  32. Fitzpatrick E, Bourke B, Drumm B, Rowland M. The incidence of cyclic vomiting syndrome in children: population-based study. Am J Gastroenterol. 2008 Apr. 103(4):991-5; quiz 996. [View Abstract]
  33. Hikita T, Kodama H, Ogita K, Kaneko S, Nakamoto N, Mimaki M. Cyclic Vomiting Syndrome in Infants and Children: A Clinical Follow-Up Study. Pediatr Neurol. 2016 Jan 7. [View Abstract]
  34. Venkatesan T, Tarbell S, Adams K, McKanry J, Barribeau T, Beckmann K, et al. A survey of emergency department use in patients with cyclic vomiting syndrome. BMC Emerg Med. 2010 Feb 24. 10:4. [View Abstract]
  35. Zeevenhooven J, Koppen IJ, Benninga MA. The New Rome IV Criteria for Functional Gastrointestinal Disorders in Infants and Toddlers. Pediatr Gastroenterol Hepatol Nutr. 2017 Mar. 20 (1):1-13. [View Abstract]
  36. [Guideline] Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr. 2008 Sep. 47(3):379-93. [View Abstract]
  37. Pfau BT, Li BU, Murray RD, et al. Differentiating cyclic from chronic vomiting patterns in children: quantitative criteria and diagnostic implications. Pediatrics. 1996 Mar. 97(3):364-8. [View Abstract]
  38. Hoyt CS, Stickler GB. A study of 44 children with the syndrome of recurrent (cyclic) vomiting. Pediatr. 1960. 25:775-80. [View Abstract]
  39. Li BU. Cyclic vomiting: the pattern and syndrome paradigm. J Pediatr Gastroenterol Nutr. 1995. 21 Suppl 1:S6-10. [View Abstract]
  40. Venkatasubramani N, Venkatesan T, Li BUK. Extreme Emesis: Cyclic Vomiting Syndrome. Practical Gastroenterology. September 2007. 31:21-34.
  41. Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004 Nov. 53(11):1566-70. [View Abstract]
  42. Donnino MW, Cocchi MN, Miller J, Fisher J. Cannabinoid hyperemesis: A case series. J Emerg Med. 2009 Sep 16. [View Abstract]
  43. Hejazi RA, Lavenbarg TH, Foran P, McCallum RW. Who are the non-responders to standard treatment with tricyclic antidepressant agents for cyclic vomiting syndrome in adults? A large single center experience. Aliment Pharmacol Ther. 2009 Oct 10. [View Abstract]
  44. Choung RS, Locke GR 3rd, Lee RM, Schleck CD, Zinsmeister AR, Talley NJ. Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males. Neurogastroenterol Motil. 2012 Jan. 24(1):20-6, e1. [View Abstract]
  45. Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012 Feb. 87(2):114-9. [View Abstract]
  46. Wallace EA, Andrews SE, Garmany CL, Jelley MJ. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. South Med J. 2011 Sep. 104(9):659-64. [View Abstract]
  47. Li BU, Murray RD, Heitlinger LA, et al. Heterogeneity of diagnoses presenting as cyclic vomiting. Pediatrics. 1998 Sep. 102(3 Pt 1):583-7. [View Abstract]
  48. Li BU. Cyclic vomiting syndrome and abdominal migraine: periodic syndromes with gastrointestinal symptoms. Int Semin Pediatr Gastroenterol Nutr. 2000. 9(3):1-8.
  49. Olson AD, Li BU. The diagnostic evaluation of children with cyclic vomiting: A cost-effectiveness assessment. Pediatr. 2002. 141:724-8. [View Abstract]
  50. Forbes D, Withers G. Prophylactic therapy in cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr. 1995. 21 Suppl 1:S57-9. [View Abstract]
  51. Lee LY, Abbott L, Mahlangu B, Moodie SJ, Anderson S. The management of cyclic vomiting syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2012 Sep. 24(9):1001-6. [View Abstract]
  52. Hejazi RA, McCallum RW. Cyclic vomiting syndrome: treatment options. Exp Brain Res. 2014 Aug. 232(8):2549-52. [View Abstract]
  53. Moses J, Keilman A, Worley S, Radhakrishnan K, Rothner AD, Parikh S. Approach to the diagnosis and treatment of cyclic vomiting syndrome: a large single-center experience with 106 patients. Pediatr Neurol. 2014 Jun. 50(6):569-73. [View Abstract]
  54. Ozdemir HH, Bulut S, Berilgen MS, Kapan O, Balduz M, Demir CF. Resistant cyclic vomiting syndrome successfully responding to chlorpromazine. Acta Medica (Hradec Kralove). 2014. 57(1):28-9. [View Abstract]
  55. Li BU. Cyclic vomiting syndrome: a pediatric Rorschach test. J Pediatr Gastroenterol Nutr. 1993 Nov. 17(4):351-3. [View Abstract]
  56. Li BU. Cyclic vomiting: new understanding of an old disorder. Contemp Pediatr. 1996. 13:48-62.
  57. Hejazi RA, Reddymasu SC, Namin F, Lavenbarg T, Foran P, McCallum RW. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol. 2010 Jan. 44(1):18-21. [View Abstract]
  58. Boles RG, Lovett-Barr MR, Preston A, Li BU, Adams K. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol. 2010 Jan 28. 10:10. [View Abstract]
  59. Boles RG. High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series. BMC Neurol. 2011 Aug 16. 11:102. [View Abstract]
  60. Clouse RE, Sayuk GS, Lustman PJ, Prakash C. Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series. Clin Gastroenterol Hepatol. 2007 Jan. 5(1):44-8. [View Abstract]
  61. Kumar N, Bashar Q, Reddy N, Sengupta J, Ananthakrishnan A, Schroeder A. Cyclic Vomiting Syndrome (CVS): is there a difference based on onset of symptoms - pediatric versus adult?. BMC Gastroenterol. 2012 May 28. 12(1):52. [View Abstract]
  62. Benson JM, Zorn SL, Book LS. Sumatriptan in the treatment of cyclic vomiting. Ann Pharmacother. 1995 Oct. 29(10):997-9. [View Abstract]
  63. Calhoun AH, Pruitt AP. Injectable sumatriptan for cyclic vomiting syndrome in adults: a case series. Headache. 2014 Oct. 54(9):1526-30. [View Abstract]
  64. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005 Aug. 116(3):276-88. [View Abstract]
  65. Vardanyan A, Wang R, Vanderah TW, Ossipov MH, Lai J, Porreca F. TRPV1 receptor in expression of opioid-induced hyperalgesia. J Pain. 2009 Mar. 10(3):243-52. [View Abstract]
  66. Tarbell SE, Li BU. Anxiety Measures Predict Health-Related Quality of Life in Children and Adolescents with Cyclic Vomiting Syndrome. J Pediatr. 2015 Sep. 167 (3):633-638.e1. [View Abstract]
  67. Badihian N, Saneian H, Badihian S, Yaghini O. Prophylactic Therapy of Cyclic Vomiting Syndrome in Children: Comparison of Amitriptyline and Cyproheptadine: A Randomized Clinical Trial. Am J Gastroenterol. 2018 Jan. 113 (1):135-140. [View Abstract]
  68. Taranukha T, Charan Suresh Kumar V, Seamon A, Sahr N, Szabo A, Venkatesan T. Depression, young age, chronic marijuana use, and interepisodic symptoms predict psychological distress in patients with cyclic vomiting syndrome. Neurogastroenterol Motil. 2018 Apr. 30 (4):e13245. [View Abstract]

Cyclic versus chronic temporal patterns of recurrent vomiting. Number of emeses is plotted over 2-month period. Chronic pattern, represented by thin dashed line, has low grade on nearly daily basis (eg, gastroesophageal reflux). Cyclic pattern, represented by heavy solid line, involves high-intensity episodes intermittently once every several weeks (eg, cyclic vomiting syndrome).

Cyclic versus chronic temporal patterns of recurrent vomiting. Number of emeses is plotted over 2-month period. Chronic pattern, represented by thin dashed line, has low grade on nearly daily basis (eg, gastroesophageal reflux). Cyclic pattern, represented by heavy solid line, involves high-intensity episodes intermittently once every several weeks (eg, cyclic vomiting syndrome).

Characteristic Adults



(n = 104)



Children



(n = 147)



Number of ED visits per patient with CVS (median)15 (range, 1-200)10 (range, 1-175)
Number of ED visits before diagnosis of CVS (median)7 (range, 1-150)5 (range, 0-65)
Diagnosis not made in ED89 (93%)119 (93%)
Diagnosis not recognized in ED in patients with established diagnosis of CVS84 (88%)97 (80%)
Number of different EDs visited (mean ± SD)4.69 ± 4.722.6 ± 2.42
CVS = cyclic vomiting syndrome; ED = emergency department; SD = standard deviation.
Feature Children Adults
Age of onset4.8 years (earliest, 6 days)35 years (latest, 73 years)
Delay in diagnosis2.6 years8 years
Female-to-male ratio57:4317:24
FrequencyEvery 2-4 weeksEvery 3 months
Duration (mean)1-2 days (range, 1-10 days)6 days (range, 1-21 days)
Periodicity49%Not reported
Early morning onset42%50%
Stereotypical episodes99%85%
Prodrome72%, 1.5 hours93%
SymptomsNausea, anorexia, pallorNausea, epigastric pain
Recovery to oral feeding6 hours24 hours
Relieving factorsDeep sleepHot bath or shower (56%)
Precipitating factorsStress (47%), infection (31%)Menses (57%), anxiety
Comorbid conditionsAnxietyNot reported
Inter episodic nausea< 6%63%
Coalescence of episodesFew50%
Vomiting6 episodes/hr at peak, bile (81%)8.5 episodes/hr
Systemic symptomsPallor, salivation, listlessnessIntense thirst (33%)
GI symptomsAnorexia, nausea, diarrhea, abdominal painAbdominal pain, diarrhea
Neurologic symptomsHeadache, photophobia, phonophobia, abdominal painIrritability, confusion
Natural history=28% progress to migraineNot reported
Family history82%57%
ComplicationsDehydration, esophagitisDehydration, esophagitis, laparotomy (18%)
Morbidity14-25 days of missed school per year32% completely disabled